Tag: bispecific T-cell engager

Home / bispecific T-cell engager

Categories

Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer

May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung cancer (ES-SCLC) in patients wh...
bispecific-t-cell-engager

Scan the code